MTMR5 Activators
MTMR5 Activators encompass a range of compounds that, by influencing the cellular levels of PI3P and related phosphoinositides, could indirectly enhance the enzymatic activity of MTMR5. As a phosphatase specific to certain phosphoinositides, MTMR5's activity is inherently tied to the availability of its substrates within the cell. Thus, any modulation in the synthesis or degradation pathways of these substrates can have a downstream effect on MTMR5's function. For instance, altering the activity of enzymes upstream, like PI3K, affects the equilibrium of PI3P. Inhibitors like PI-103, AS605240, IC87114, and CAL-101, by damping the activity of PI3K isoforms, can lead to altered PI3P availability, amplifying the activity of MTMR5 due to increased substrate accessibility.
Furthermore, compounds that modulate the metabolism of lipids, such as fenofibrate and miltefosine, can indirectly influence the activity of MTMR5. These compounds do not directly interact with MTMR5 but can alter the lipid composition of cellular membranes, thereby modulating the pool of phosphoinositides that MTMR5 can dephosphorylate. In addition, molecules like zoledronic acid impact prenylation processes, which are crucial for the membrane association of several kinases and phosphatases, including those that regulate phosphoinositide metabolism. Such alterations in lipid signaling pathways can potentiate the functional capacity of MTMR5 to regulate PI3P levels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K. Similar to wortmannin, LY294002 would indirectly enhance the functional activity of MTMR5 by modulating the levels of PI3P, thereby providing more of the substrate for MTMR5 to dephosphorylate. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine is an autophagy inhibitor that works by inhibiting PI3Ks, leading to changes in PI3P levels. This could enhance MTMR5 activity by increasing the available substrate for dephosphorylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can have downstream effects on PI3K signaling and potentially affect PI3P levels. This, in turn, can influence MTMR5's activity by providing more substrate for phosphatase activity. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic acid, a bisphosphonate, can affect prenylation and thereby influence PI3K signaling. This indirect effect could lead to changes in PI3P levels and subsequently enhance MTMR5 activity. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα) and can influence the metabolism of lipids, including phosphoinositides. This could indirectly affect the substrate availability for MTMR5. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $33.00 | ||
Clofibrate, similar to fenofibrate, is a PPARα agonist and can modulate lipid metabolism. Its effects on phosphoinositides could enhance the activity of MTMR5 by altering substrate levels. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a beta-blocker, has been shown to affect phospholipid metabolism. While it is not a direct activator, its influence on lipid signaling could impact the levels of substrates available to MTMR5. | ||||||
Miltefosine | 58066-85-6 | sc-203135 | 50 mg | $81.00 | 8 | |
Miltefosine is an alkylphosphocholine that affects phospholipid metabolism. By altering the levels of phospholipids, it could indirectly enhance the functional activity of MTMR5 by providing more of the specific substrate that MTMR5 acts upon. | ||||||